PO.2.30 IGG/IGM autoantibody ratios do not relate to progression from incomplete systemic lupus erythematosus to systemic lupus erythematosus. (27th September 2022)

• Record Type: Journal Article
• Authors: Henning, S; Westra, J; Nedomova, V; Horvath, B; Bootsma, H; De Leeuw, K
• Is Part Of: Lupus science & medicine. Volume 9(2022)Supplement 2
• Page Start: A37
• Page End: A38
• Publication Date: 2022-09-27
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2022-elm2022.60
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Purpose: To identify whether IgG/IgM autoantibody ratios differ between patients with incomplete systemic lupus erythematosus (iSLE), patients with SLE and healthy controls (HC) and to assess whether IgG/IgM autoantibody ratios are related to progression from iSLE to SLE. Methods: In total, 34 iSLE patients, 41 SLE patients with quiescent disease and 22 HC were included in this cohort study. Patients were classified as iSLE if they met one clinical and one immunological criterion but less than four criteria of the Systemic Lupus International Collaborating Clinics (SLICC) criteria. Clinical assessment and blood collection was performed at baseline. Patients with iSLE received follow-up every six months up to five years or until progression to SLE. IgG and IgM levels for anti-dsDNA, anti-Ro52 and anti-Ro60 were measured by fluoro-enzyme-immuno-assay in serum samples obtained at baseline and follow-up. Optical density values were used for calculating the autoantibody ratios. Results: Cross-sectionally, anti-Ro52, anti-dsDNA and total IgG/IgM ratios did not differ between groups. Anti-Ro60 IgG/IgM ratios were significantly elevated in iSLE patients and SLE patients compared to HCs. There was no correlation between IgG/IgM ratios and interferon signature, SLEDAI score, complement levels or number of SLICC classification criteria at baseline. Of the 34 iSLE patients, six patients progressed to SLE and one patient developed primary Sjögren's syndrome within five years. One patient that progressed to SLE showed an increase in anti-Ro52 and anti-Ro60 IgG/IgM ratio prior to progression. This increase was mainly due to an increase in anti-Ro52 and anti-Ro60 IgG autoantibodies. This finding was not observed in the other five progressors. IgG/IgM ratios were relatively constant during follow-up in non-progressors. Conclusion: Anti-Ro60 IgG/IgM ratios were significantly elevated in iSLE and SLE patients compared to HCs at baseline. IgG/IgM autoantibody ratios did not differ between iSLE patients that progressed to SLE and iSLE patients that did not progress.